Histogenics files IPO for $65M

Histogenics, a biotech company focused on developing an implantable tissue repair platform for cartilage damage to the knee, filed with the U.S. Securities and Exchange Commission to raise up to $65 million in an initial public offering, according to a Renaissance Capital IPO News report.

The company plans to use the funds to develop and complete clinical trials for its regenerative medicine platform, NeoCart. Histogenics plans to list on the NASDAQ under the symbol HSGX. Cowen & Company, Needham and Canaccord Genuity are the joint bookrunners on the deal. No pricing terms were disclosed.

Histogenics files IPO for $65M

More articles on devices:

Next Up in Orthopedic

The Orthopaedic Research and Education Foundation adds to executive team

U of Utah surgeons complete 1st procedure with Reverse ChondroMatch system

Tennessee clinic adds hand surgeon

More articles on devices:

A guide for evaluating the impact of ambient AI on clinicians

Next Up in Orthopedic

The Orthopaedic Research and Education Foundation adds to executive team

U of Utah surgeons complete 1st procedure with Reverse ChondroMatch system

Tennessee clinic adds hand surgeon

Join the spine leaders & surgeons who start their day with Becker's